Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672633 · ClinicalTrials.gov registry record · Phase 2
Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides
A Phase 2 study, sponsored by Boston Children's Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00672633 is a Phase 2 study that was terminated before completion, run by Boston Children's Hospital. The registered enrollment target is 25 participants.
The verdict
NCT00672633, a Phase 2 study, was terminated before completion, sponsored by Boston Children's Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators will conduct a randomized clinical trial to evaluate the efficacy of Lovaza (formerly known as Omacor) in reducing triglyceride levels in youth ages 10-19 years old whose baseline triglycerides range from 150 mg/dl to 1000 mg/dl. Seventy subjects will be recruited at baseline and randomized to the treatment condition, Lovaza 4 grams/day for 6 months or the control condition, a corn oil placebo, 4 tablets a day for 6 months. Participants in both the treatment and control groups will receive the standard of care, which is dietary advice to follow a low, refined carbohydrate and low saturated fat diet that emphasizes increasing intake of fruits and vegetables and eating 2 servings per week of fishes rich in omega-3 fatty acids, consistent with the American Heart Association recommendations. The primary outcome will be change in fasting triglycerides from baseline to 3 months. The investigators hypothesize that patients who receive LOVAZA will have significantly greater reductions in plasma triglyceride levels when compared to patients on placebo at 3 months.
Interventions
- DRUG Placebo
- DRUG Lovaza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00672633
The ClinicalTrials.gov registry entry for NCT00672633 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00672633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00672633 about?
NCT00672633 is a clinical study titled "Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides". The investigators will conduct a randomized clinical trial to evaluate the efficacy of Lovaza (formerly known as Omacor) in reducing triglyceride levels in youth ages 10-19 years old whose baseline triglycerides range from 150 mg/dl to 1000 mg/dl. Seventy subjects will be recruited at baseline and r...
What is the current status of trial NCT00672633?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-04. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00672633?
The interventions under investigation include: Placebo (DRUG), Lovaza (DRUG).
Who is sponsoring clinical trial NCT00672633?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.